glimepiride / Generic mfg. - LARVOL DELTA

The GOLD-PCP Study: Clinician Insights on Person-Centric Packaging Design of a Triple Fixed-Dose Combination in Type 2 Diabetes Care. (PubMed, Cureus) - "Clinicians perceived PCP as beneficial for adherence support and therapy management in type 2 diabetes. However, further patient-centered studies using objective adherence metrics are needed to validate these perceptions and determine causal relationships between packaging design and adherence outcomes."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Common genetic variants near SLC2A2 and glycemic response to glimepiride in the GRADE comparative effectiveness clinical trial. (PubMed, medRxiv) - P3 | "We conducted a pharmacogenomic genome-wide association study (GWAS) in the Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness (GRADE) Study to identify genetic predictors of glycemic response to insulin glargine, glimepiride, liraglutide, and sitagliptin, when added to metformin in a diverse population. In conclusion, genetic variation influences glycemic response to medications, with SLC2A2 emerging as a key determinant of sulfonylurea response. Clinical Trial registration number: NCT01794143."

HEOR • Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • SLC2A2

ON TARGET DM: Comparison of Type 2 Diabetes Pharmacotherapy Regimens (clinicaltrials.gov) - P=N/A | N=241981 | Completed | Sponsor: Kaiser Permanente | Recruiting ➔ Completed | Trial completion date: Aug 2025 ➔ Mar 2025

Trial completion • Trial completion date • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes (clinicaltrials.gov) - P4 | N=172 | Completed | Sponsor: Bahria University | Recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Noninsulin drugs for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Impact of fig leaf extract (Ficus carica L.) on GLUT-2 expression in pancreatic b cells and hepatic cells of Wistar rats induced by streptozotocin-nicotinamide. (PubMed, Pediatr Endocrinol Diabetes Metab) - "A glimepiride-treated group served as the positive control...Although the observed improvements were not statistically significant, the trends suggest potential antidiabetic activity, particularly at higher doses. The lack of significance may be attributed to the dosage of the extract used in this study."

Journal • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Renal Functional Reserve Predicts GFR Response to Empagliflozin but Not Linagliptin or Sulfonylureas in Patients with Type 2 Diabetes (KIDNEY WEEK 2025) - "Patients received EMPA (10mg; N=20), LINA (5mg; N=27) or SU (glimepiride 1mg or gliclazide 30mg; N=24), added to stable metformin. Conclusion Postprandial RFR links to the acute GFR dip with EMPA, but not GFR changes in response to LINA or SU. As initial GFR-dipping is associated with long-term kidney benefit, RFR may be a potential biomarker to personalize SGLT2i-therapy."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Prices of Anti-Diabetic Drugs Sold in Private Pharmacies in Côte d'Ivoire, 2023: A Secondary Analysis. (PubMed, Clinicoecon Outcomes Res) - "Median prices for oral antidiabetics ranged from US$4.5 to US$11.3 for Metformin 500mg, from US$1 (Glibenclamid 5mg) to US$27.7 (Glimepiride 1mg) for Sulfonylureas, from US$13.9 (Sitagliptin 50mg) to US$26.3 (Vidagliptin 50mg) for DDP-4 inhibitors and from US$24.2 (Empaglifozin 25mg) to US$39.4 (Empaglifozin 10mg) for SGLT-2 inhibitors. Prices of antidiabetic drugs were higher than the international references prices. The development of a pricing policy emphasizing added value and price referencing, together with the development of a local generics industry, could guarantee prices that are accessible to the population and bearable by universal health coverage."

Journal • Diabetes • Metabolic Disorders

Effects on major adverse cardiovascular events in persons treated with sotagliflozin: Prespecified pooled analyses of the Phase 3 type 2 diabetes program (AHA 2025) - "Of these, 2,904 participants were treated with sotagliflozin (200 or 400 mg QD), while 2,196 were in an All-Comparators group (pooling placebo, empagliflozin, and glimepiride). Two independent data sources (9 cardiometabolic Phase 3 studies and the SCORED CV outcomes trial), including approximately 15,000 participants, support a reduction in MACE with sotagliflozin in a broad group of persons with T2D, and reinforce the role of sotagliflozin in reducing atherosclerotic cardiovascular risk."

Adverse events • P3 data • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Myocardial Infarction • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

WHEN SWEET TURNS SOUR: PERSISTENT SULFONYLUREA-INDUCED HYPOGLYCEMIA IN RENAL FAILURE REQUIRING OCTREOTIDE DRIP (CHEST 2025) - "When managing diabetes with underlying chronic kidney disease, it is essential to carefully consider therapeutic agents, as demonstrated by our patient on glimepiride... This case underscores the challenges in managing severe sulfonylurea toxicity and emphasizes the potential role of octreotide as an effective treatment for refractory hypoglycemia. Given the availability of more modern therapies with a lower risk of adverse effects, sulfonylureas should be used cautiously in patients with chronic kidney disease."

Cardiovascular • Chronic Kidney Disease • CNS Disorders • Diabetic Nephropathy • Hypoglycemia • Nephrology • Renal Disease • Respiratory Diseases • Severe Hypoglycemia

A digital twin of glimepiride for personalized and stratified diabetes treatment. (PubMed, Front Pharmacol) - "Increased glimepiride exposure was predicted in individuals with hepatic dysfunction or specific CYP2C9 variants, highlighting substantial genetic and physiological effects. This digital twin provides mechanistic insights into pharmacokinetic variability and serves as an in silico platform for exploring individualized dosing and patient stratification strategies, laying the foundation for clinical decision support tools to improve T2DM management."

Journal • Diabetes • Hepatology • Liver Failure • Metabolic Disorders • Type 2 Diabetes Mellitus • CYP2C9

A dual in silico-in vitro assessment of nine glimepiride apis: efficacy and oxidative stress protection in type 2 diabetes. (PubMed, J Diabetes Metab Disord) - "The observed differences in the efficacy of the Glimepiride APIs were likely due to factors such as variations in bioavailability, formulation composition, and pharmacokinetic properties. The findings highlight the importance of assessing these factors when evaluating generic formulations for therapeutic use in T2DM management."

Journal • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • AKR1B1

Comparative Weight Change With Initiation and Adherence to Common Medications for Type 2 Diabetes. (PubMed, Obesity (Silver Spring)) - "Initiation/adherence to GLP-1RAs and SGLT-2s over 24 months could result in average weight losses of 5.15 kg and 6.71 kg, respectively."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Type 2 Diabetes Mellitus

Reappraisal of cardiometabolic stress in type 2 diabetes mellitus patients receiving glimepiride versus insulin under bitherapy. (PubMed, J Family Med Prim Care) - "The glimepiride-metformin combination was more effective against vascular dysfunction, sympathovagal balance, metabolic stress, and inflammation. Cardiometabolic mediators of cardiovascular risk were higher in metformin-insulin-treated patients, despite achieving similar glycemic targets."

Journal • Cardiovascular • Diabetes • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus • CRP • ENG

Synergism of Synthetic Sulfonamides and Natural Antioxidants for the Management of Diabetes Mellitus Associated with Oxidative Stress. (PubMed, Curr Issues Mol Biol) - "Promising results have been achieved through dual therapies that combine antioxidants (such as sesame oil, naringin, alpha-lipoic acid, resveratrol, and quercetin) with sulfonylureas (including glipizide, glibenclamide, gliclazide, and glimepiride). These recent advancements in synthetic sulfonamide research point to a promising future in diabetes management, especially considering the dual functionalities demonstrated by in vivo studies-specifically, their antidiabetic and antioxidant effects. Moreover, the synergy between sulfonamides and other antioxidant agents represents a beneficial strategy for optimizing future chemical structures, potentially allowing for their integration into personalized treatments aimed at combating T2DM."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparative cardiovascular risk of sulfonylureas with low- and high-affinities for cardiac mitochondrial adenosine triphosphate-sensitive potassium channels versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A cohort study. (PubMed, Diabetes Obes Metab) - "Initiating low-affinity mitoKATP-channel sulfonylureas demonstrated cardiovascular safety comparable to DPP-4i, whereas high-affinity sulfonylureas were linked to increased cardiovascular risk and all-cause mortality. These findings suggest low-affinity sulfonylureas are a safer alternative to high-affinity agents and as safe as DPP-4i. They may be appropriate for individuals with diabetes when newer therapies are inaccessible or unnecessary."

Journal • Cardiovascular • Diabetes • Ischemic stroke • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

Patterns of Prescription Switching in a Uniform-Pricing System for Multi-Source Drugs: A Retrospective Population-Based Cohort Study. (PubMed, Healthcare (Basel)) - "Switching rates varied substantially (coefficient of variation = 227%) by physician practice setting (e.g., public health center branches: 26%; tertiary hospitals: 15%) and by drug market size (e.g., glimepiride: 29%; cilnidipine: 1%). In Korea, physicians frequently switch prescriptions between originator and generic drugs, even as generic substitution at the pharmacy level remains uncommon. The substantial variation in MSPS across provider settings and drug markets-but not by patient characteristics-underscores the need for targeted pharmacy benefit policies to promote effective substitutability and competition among multi-source drugs."

Journal • Pricing • Retrospective data • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders

Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort. (PubMed, Diabetes Care) - "ECG abnormalities, including those reflecting CAN, are common in individuals with T2D <10 years and more so in those with certain cardiovascular risk factors. The development of major ECG abnormalities may be lower with liraglutide."

Journal • Cardiovascular • Diabetes • Metabolic Disorders • Pain • Type 2 Diabetes Mellitus

Hypoglycemic and Hypolipidemic Effects of Leonotis mollisima Aqueous Leaf Extract in Type 2 Diabetic Rats. (PubMed, J Exp Pharmacol) - "Rats received Leonotis mollissima extract (250, 500, 1000 mg/kg) or glimepiride (5 mg/kg; sulfonylurea insulin secretagogue) for 28 days...The extract's ability to improve glycemic control, lipid profiles, and pancreatic histoarchitecture suggests its potential as a therapeutic agent for managing diabetes and its complications. Further research is recommended to isolate active compounds and evaluate their efficacy in clinical trials."

Journal • Preclinical • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus

The Diabetes and Ramadan global survey: outcomes among people with type 2 diabetes using sulfonylureas vs non-insulin antidiabetic agents (EASD 2025) - "Numerous studies have demonstrated that second-generation sulfonylureas (SU) such as gliclazide and glimepiride are preferable to older drugs within this class...Metformin and DPP4-inhibitors were the most frequently used concomitant medications... In this global survey, T2D patients using modern SU were able to fast at the same frequency as non-SU users. Among 2nd generation SU, the gliclazide MR group had the highest rates of fasting days and the lowest rates of symptomatic hypoglycaemia."

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third-line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP-4 inhibitors: A multicentre, phase 4 randomized controlled trial. (PubMed, Diabetes Obes Metab) - "The addition of empagliflozin, pioglitazone, or glimepiride to metformin and DPP-4 inhibitors significantly improved glycaemic control in patients with T2D. The selection of a third agent should be individualized based on the patient characteristics."

Journal • P4 data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluation of three mechanisms of action (SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas) in treating type 2 diabetes with heart failure: a systematic review and network meta-analysis of RCTs. (PubMed, Front Endocrinol (Lausanne)) - "A Bayesian network meta-analysis was utilized to integrate direct and indirect evidence, facilitating a comparative ranking of various SGLT2 inhibitors-canagliflozin (CANA), ipragliflozin (IPRA), empagliflozin (EMPA), remogliflozin (REMO), licogliflozin (LICO), and dapagliflozin (DAPA)-as well as one GLP-1 receptor agonist-semaglutide (SEMA)-and a sulfonylurea-glimepiride (GLIM)-with respect to their efficacy and safety profiles. Despite its moderate efficacy, GLIM remains a viable choice for certain patients due to its favorable safety profile and cost-effectiveness. Collectively, these findings provide essential evidence-based insights to guide individualized therapeutic strategies in type 2 diabetes complicated by heart failure."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Hypoglycemia • Infectious Disease • Metabolic Disorders • Nephrology • Obesity • Type 2 Diabetes Mellitus

A multicenter, randomized, open-label clinical trial of early combination therapy with methylprednisolone sodium succinate and glimepiriden in patients with acute large vessel occlusion stroke (ChiCTR) - P=N/A | N=160 | Recruiting | Sponsor: Lanzhou University Second Hospital; Lanzhou University Second Hospital

New trial • Cardiovascular • Hypoglycemia • Ischemic stroke

Unmasking Diabetes in a Young Adult Male: A Case Report. (PubMed, Cureus) - "A trial of glimepiride, a sulfonylurea, led to marked glycemic improvement, allowing complete discontinuation of insulin within six months...This report underscores the importance of considering MODY in young patients with atypical diabetes presentations, especially those with a strong family history and antibody-negative, insulin-independent diabetes. Early recognition can guide appropriate therapy, reduce treatment burden, and prompt family screening."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • HNF1A

Sodium-glucose co-transporter 2 inhibitors reduce the intravitreal anti-VEGF treatment necessity in eyes with early diabetic macular oedema: A post-hoc analysis focusing on the fellow eye of the COMET trial. (PubMed, Diabetes Obes Metab) - "Systemic SGLT2i therapy reduced the need for intravitreal anti-VEGF treatment in eyes with early and mild DMO. These results suggest that SGLT2i may be effective in preventing the progression of early and mild DMO."

Journal • Retrospective data • Diabetic Macular Edema • Diabetic Retinopathy • Macular Edema • Ophthalmology • Retinal Disorders